Roche Holding Ltd (RHHBY) CEO Severin Schwan on Q3 2018 Results - Earnings Call Transcript [Seeking Alpha]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Seeking Alpha
Roche Holding Ltd ( OTCQX:RHHBY ) Q3 2018 Earnings Conference Call October 17, 2018 8:00 AM ET Executives Severin Schwan - Chief Executive Officer Dan O’Day - Chief Executive Officer, Roche Pharmaceuticals Michael Heuer - Chief Executive Officer, Roche Diagnostics Alan Hippe - Chief Financial Officer Analysts Richard Vosser - JPMorgan Luisa Hector - Exane Sachin Jain - Bank of America Matthew Weston - Credit Suisse Jack Scannell - UBS Tim Race - Deutsche Bank Sam Fazeli - Bloomberg Intelligence Andrew Baum - Citi Keyur Parekh - Goldman Sachs Naresh Chouhan - New Street Research Emmanuel Papadakis - Barclays Steve Scala - Cohen Operator Ladies and gentlemen, thank you for standing by. Welcome to the Roche’s Third Quarter 2018 Audio Webcast and Conference Call. I am Irwina, the Chorus Call operator. [Operator Instructions] The conference must not be recorded for publication or broadcast. At this time, it’s my pleasure to hand over to Seve
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer [Yahoo! Finance]Yahoo! Finance
- FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung CancerBusiness Wire
- Roche's subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS [Yahoo! Finance]Yahoo! Finance
- Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MSBusiness Wire
- Genentech's Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study [Yahoo! Finance]Yahoo! Finance